Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Regulation of eIF4F translation initiation complex by the peptidyl prolyl isomerase FKBP7 in taxane-resistant prostate cancer.

Garrido MF, Martin NJ, Bertrand M, Gaudin C, Commo F, El Kalaany N, Al Nakouzi N, Fazli L, Del Nery E, Camonis J, Perez F, Lerondel S, LE Pape A, Gleave ME, Loriot Y, Desaubry L, Vagner S, Fizazi K, Chauchereau A.

Clin Cancer Res. 2018 Oct 15. pii: clincanres.0704.2018. doi: 10.1158/1078-0432.CCR-18-0704. [Epub ahead of print]

PMID:
30322877
2.

Apparent slip of shear thinning fluid in a microchannel with a superhydrophobic wall.

Patlazhan S, Vagner S.

Phys Rev E. 2017 Jul;96(1-1):013104. doi: 10.1103/PhysRevE.96.013104. Epub 2017 Jul 10.

PMID:
29347200
3.

Regulation of RNA polymerase III transcription during transformation of human IMR90 fibroblasts with defined genetic elements.

Durrieu-Gaillard S, Dumay-Odelot H, Boldina G, Tourasse NJ, Allard D, André F, Macari F, Choquet A, Lagarde P, Drutel G, Leste-Lasserre T, Petitet M, Lesluyes T, Lartigue-Faustin L, Dupuy JW, Chibon F, Roeder RG, Joubert D, Vagner S, Teichmann M.

Cell Cycle. 2018;17(5):605-615. doi: 10.1080/15384101.2017.1405881. Epub 2018 Jan 22.

PMID:
29171785
4.

The G-Quadruplex-Specific RNA Helicase DHX36 Regulates p53 Pre-mRNA 3'-End Processing Following UV-Induced DNA Damage.

Newman M, Sfaxi R, Saha A, Monchaud D, Teulade-Fichou MP, Vagner S.

J Mol Biol. 2017 Oct 27;429(21):3121-3131. doi: 10.1016/j.jmb.2016.11.033. Epub 2016 Dec 7.

PMID:
27940037
5.

Molecular Pathways: The eIF4F Translation Initiation Complex-New Opportunities for Cancer Treatment.

Malka-Mahieu H, Newman M, Désaubry L, Robert C, Vagner S.

Clin Cancer Res. 2017 Jan 1;23(1):21-25. doi: 10.1158/1078-0432.CCR-14-2362. Epub 2016 Oct 27. Review.

6.

DNA-Damage Response RNA-Binding Proteins (DDRBPs): Perspectives from a New Class of Proteins and Their RNA Targets.

Dutertre M, Vagner S.

J Mol Biol. 2017 Oct 27;429(21):3139-3145. doi: 10.1016/j.jmb.2016.09.019. Epub 2016 Sep 29. Review.

PMID:
27693651
7.

Synergistic effects of eIF4A and MEK inhibitors on proliferation of NRAS-mutant melanoma cell lines.

Malka-Mahieu H, Girault I, Rubington M, Leriche M, Welsch C, Kamsu-Kom N, Zhao Q, Desaubry L, Vagner S, Robert C.

Cell Cycle. 2016 Sep 16;15(18):2405-9. doi: 10.1080/15384101.2016.1208862. Epub 2016 Aug 11.

8.

Correction for Colman et al., Genome-Wide Analysis of Host mRNA Translation during Hepatitis C Virus Infection.

Colman H, Berre-Scoul CL, Hernandez C, Pierredon S, Bihouée A, Houlgatte R, Vagner S, Rosenberg AR, Féray C.

J Virol. 2016 May 27;90(12):5846. doi: 10.1128/JVI.00507-16. Print 2016 Jun 15. No abstract available.

9.

hnRNP A1-mediated translational regulation of the G quadruplex-containing RON receptor tyrosine kinase mRNA linked to tumor progression.

Cammas A, Lacroix-Triki M, Pierredon S, Le Bras M, Iacovoni JS, Teulade-Fichou MP, Favre G, Roché H, Filleron T, Millevoi S, Vagner S.

Oncotarget. 2016 Mar 29;7(13):16793-805. doi: 10.18632/oncotarget.7589.

10.

Translational regulation of the mRNA encoding the ubiquitin peptidase USP1 involved in the DNA damage response as a determinant of Cisplatin resistance.

Sourisseau T, Helissey C, Lefebvre C, Ponsonnailles F, Malka-Mahieu H, Olaussen KA, André F, Vagner S, Soria JC.

Cell Cycle. 2016;15(2):295-302. doi: 10.1080/15384101.2015.1120918. Erratum in: Cell Cycle. 2016;15(6):868.

11.

Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAF-CRAF Heterodimerization.

Boussemart L, Girault I, Malka-Mahieu H, Mateus C, Routier E, Rubington M, Kamsu-Kom N, Thomas M, Tomasic G, Agoussi S, Breckler M, Laporte M, Lacroix L, Eggermont AM, Cavalcanti A, Grange F, Adam J, Vagner S, Robert C.

Cancer Res. 2016 Mar 15;76(6):1476-84. doi: 10.1158/0008-5472.CAN-15-2900-T. Epub 2016 Jan 29.

12.

TRM6/61 connects PKCα with translational control through tRNAi(Met) stabilization: impact on tumorigenesis.

Macari F, El-Houfi Y, Boldina G, Xu H, Khoury-Hanna S, Ollier J, Yazdani L, Zheng G, Bièche I, Legrand N, Paulet D, Durrieu S, Byström A, Delbecq S, Lapeyre B, Bauchet L, Pannequin J, Hollande F, Pan T, Teichmann M, Vagner S, David A, Choquet A, Joubert D.

Oncogene. 2016 Apr 7;35(14):1785-96. doi: 10.1038/onc.2015.244. Epub 2015 Aug 3.

PMID:
26234676
13.

Steady-state deformation behavior of confined composite droplets under shear flow.

Patlazhan S, Vagner S, Kravchenko I.

Phys Rev E Stat Nonlin Soft Matter Phys. 2015 Jun;91(6):063002. Epub 2015 Jun 4.

PMID:
26172787
14.

eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies.

Boussemart L, Malka-Mahieu H, Girault I, Allard D, Hemmingsson O, Tomasic G, Thomas M, Basmadjian C, Ribeiro N, Thuaud F, Mateus C, Routier E, Kamsu-Kom N, Agoussi S, Eggermont AM, Désaubry L, Robert C, Vagner S.

Nature. 2014 Sep 4;513(7516):105-9. doi: 10.1038/nature13572. Epub 2014 Jul 27.

PMID:
25079330
15.

Dramatic response to radiotherapy combined with vemurafenib. Is vemurafenib a radiosensitizer?

Baroudjian B, Boussemart L, Routier E, Dreno B, Tao Y, Deutsch E, Blanchard P, Dhermain F, Vilcot L, Vagner S, Eggermont A, Mateus C, Robert C.

Eur J Dermatol. 2014 Mar-Apr;24(2):265-7. doi: 10.1684/ejd.2014.2300. No abstract available.

PMID:
24721778
16.

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.

Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C, Haanen J, Blank C, Wesseling J, Willems SM, Zecchin D, Hobor S, Bajpe PK, Lieftink C, Mateus C, Vagner S, Grernrum W, Hofland I, Schlicker A, Wessels LF, Beijersbergen RL, Bardelli A, Di Nicolantonio F, Eggermont AM, Bernards R.

Nature. 2014 Apr 3;508(7494):118-22. doi: 10.1038/nature13121. Epub 2014 Mar 26.

17.

DNA damage: RNA-binding proteins protect from near and far.

Dutertre M, Lambert S, Carreira A, Amor-Guéret M, Vagner S.

Trends Biochem Sci. 2014 Mar;39(3):141-9. doi: 10.1016/j.tibs.2014.01.003. Epub 2014 Feb 14. Review.

PMID:
24534650
18.

Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors.

Holderfield M, Lorenzana E, Weisburd B, Lomovasky L, Boussemart L, Lacroix L, Tomasic G, Favre M, Vagner S, Robert C, Ghoddusi M, Daniel D, Pryer N, McCormick F, Stuart D.

Cancer Res. 2014 Apr 15;74(8):2238-45. doi: 10.1158/0008-5472.CAN-13-1065-T. Epub 2014 Feb 12.

19.

Age at cancer onset in germline TP53 mutation carriers: association with polymorphisms in predicted G-quadruplex structures.

Sagne C, Marcel V, Bota M, Martel-Planche G, Nobrega A, Palmero EI, Perriaud L, Boniol M, Vagner S, Cox DG, Chan CS, Mergny JL, Olivier M, Ashton-Prolla P, Hall J, Hainaut P, Achatz MI.

Carcinogenesis. 2014 Apr;35(4):807-15. doi: 10.1093/carcin/bgt381. Epub 2013 Dec 11.

20.

Genome-wide analysis of host mRNA translation during hepatitis C virus infection.

Colman H, Le Berre-Scoul C, Hernandez C, Pierredon S, Bihouée A, Houlgatte R, Vagner S, Rosenberg AR, Féray C.

J Virol. 2013 Jun;87(12):6668-77. doi: 10.1128/JVI.00538-13. Epub 2013 Apr 3. Erratum in: J Virol. 2016 May 27;90(12 ):5846.

21.

Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients.

Boussemart L, Routier E, Mateus C, Opletalova K, Sebille G, Kamsu-Kom N, Thomas M, Vagner S, Favre M, Tomasic G, Wechsler J, Lacroix L, Robert C.

Ann Oncol. 2013 Jun;24(6):1691-7. doi: 10.1093/annonc/mdt015. Epub 2013 Feb 13.

PMID:
23406731
22.

Targeting the deregulated spliceosome core machinery in cancer cells triggers mTOR blockade and autophagy.

Quidville V, Alsafadi S, Goubar A, Commo F, Scott V, Pioche-Durieu C, Girault I, Baconnais S, Le Cam E, Lazar V, Delaloge S, Saghatchian M, Pautier P, Morice P, Dessen P, Vagner S, André F.

Cancer Res. 2013 Apr 1;73(7):2247-58. doi: 10.1158/0008-5472.CAN-12-2501. Epub 2013 Jan 28.

23.

Splicing switch of an epigenetic regulator by RNA helicases promotes tumor-cell invasiveness.

Dardenne E, Pierredon S, Driouch K, Gratadou L, Lacroix-Triki M, Espinoza MP, Zonta E, Germann S, Mortada H, Villemin JP, Dutertre M, Lidereau R, Vagner S, Auboeuf D.

Nat Struct Mol Biol. 2012 Nov;19(11):1139-46. doi: 10.1038/nsmb.2390. Epub 2012 Sep 30.

PMID:
23022728
24.

Decreased efficiency of MSH6 mRNA polyadenylation linked to a 20-base-pair duplication in Lynch syndrome families.

Decorsière A, Toulas C, Fouque F, Tilkin-Mariamé AF, Selves J, Guimbaud R, Chipoulet E, Delmas C, Rey JM, Pujol P, Favre G, Millevoi S, Vagner S.

Cell Cycle. 2012 Jul 1;11(13):2578-80. doi: 10.4161/cc.20625. Epub 2012 Jul 1. No abstract available.

PMID:
22672937
25.

G-quadruplexes in RNA biology.

Millevoi S, Moine H, Vagner S.

Wiley Interdiscip Rev RNA. 2012 Jul-Aug;3(4):495-507. doi: 10.1002/wrna.1113. Epub 2012 Apr 4. Review.

PMID:
22488917
26.

Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1.

Arnault JP, Mateus C, Escudier B, Tomasic G, Wechsler J, Hollville E, Soria JC, Malka D, Sarasin A, Larcher M, André J, Kamsu-Kom N, Boussemart L, Lacroix L, Spatz A, Eggermont AM, Druillennec S, Vagner S, Eychène A, Dumaz N, Robert C.

Clin Cancer Res. 2012 Jan 1;18(1):263-72. doi: 10.1158/1078-0432.CCR-11-1344. Epub 2011 Nov 17.

27.

Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC.

Friboulet L, Barrios-Gonzales D, Commo F, Olaussen KA, Vagner S, Adam J, Goubar A, Dorvault N, Lazar V, Job B, Besse B, Validire P, Girard P, Lacroix L, Hasmats J, Dufour F, André F, Soria JC.

Clin Cancer Res. 2011 Sep 1;17(17):5562-72. doi: 10.1158/1078-0432.CCR-11-0790. Epub 2011 Jul 12.

28.

HuR-dependent loading of miRNA RISC to the mRNA encoding the Ras-related small GTPase RhoB controls its translation during UV-induced apoptosis.

Glorian V, Maillot G, Polès S, Iacovoni JS, Favre G, Vagner S.

Cell Death Differ. 2011 Nov;18(11):1692-701. doi: 10.1038/cdd.2011.35. Epub 2011 Apr 29.

29.

Formation of the eIF4F translation-initiation complex determines sensitivity to anticancer drugs targeting the EGFR and HER2 receptors.

Zindy P, Bergé Y, Allal B, Filleron T, Pierredon S, Cammas A, Beck S, Mhamdi L, Fan L, Favre G, Delord JP, Roché H, Dalenc F, Lacroix-Triki M, Vagner S.

Cancer Res. 2011 Jun 15;71(12):4068-73. doi: 10.1158/0008-5472.CAN-11-0420. Epub 2011 Apr 15.

30.

Essential role for the interaction between hnRNP H/F and a G quadruplex in maintaining p53 pre-mRNA 3'-end processing and function during DNA damage.

Decorsière A, Cayrel A, Vagner S, Millevoi S.

Genes Dev. 2011 Feb 1;25(3):220-5. doi: 10.1101/gad.607011.

31.

Nucleotide variability and translation efficiency of the 5' untranslated region of hepatitis A virus: update from clinical isolates associated with mild and severe hepatitis.

Mackiewicz V, Cammas A, Desbois D, Marchadier E, Pierredon S, Beaulieux F, Dussaix E, Vagner S, Roque-Afonso AM.

J Virol. 2010 Oct;84(19):10139-47. doi: 10.1128/JVI.02598-09. Epub 2010 Jul 14.

32.

Alternative splicing and breast cancer.

Dutertre M, Vagner S, Auboeuf D.

RNA Biol. 2010 Jul-Aug;7(4):403-11. Epub 2010 Jul 1. Review.

PMID:
20622514
33.

Occult infection of peripheral B cells by hepatitis C variants which have low translational efficiency in cultured hepatocytes.

Durand T, Di Liberto G, Colman H, Cammas A, Boni S, Marcellin P, Cahour A, Vagner S, Féray C.

Gut. 2010 Jul;59(7):934-42. doi: 10.1136/gut.2009.192088. Epub 2010 May 4.

PMID:
20442199
34.

Exon-based clustering of murine breast tumor transcriptomes reveals alternative exons whose expression is associated with metastasis.

Dutertre M, Lacroix-Triki M, Driouch K, de la Grange P, Gratadou L, Beck S, Millevoi S, Tazi J, Lidereau R, Vagner S, Auboeuf D.

Cancer Res. 2010 Feb 1;70(3):896-905. doi: 10.1158/0008-5472.CAN-09-2703. Epub 2010 Jan 26.

35.

Molecular mechanisms of eukaryotic pre-mRNA 3' end processing regulation.

Millevoi S, Vagner S.

Nucleic Acids Res. 2010 May;38(9):2757-74. doi: 10.1093/nar/gkp1176. Epub 2009 Dec 30. Review.

36.

Widespread estrogen-dependent repression of micrornas involved in breast tumor cell growth.

Maillot G, Lacroix-Triki M, Pierredon S, Gratadou L, Schmidt S, Bénès V, Roché H, Dalenc F, Auboeuf D, Millevoi S, Vagner S.

Cancer Res. 2009 Nov 1;69(21):8332-40. doi: 10.1158/0008-5472.CAN-09-2206. Epub 2009 Oct 13.

37.

A physical and functional link between splicing factors promotes pre-mRNA 3' end processing.

Millevoi S, Decorsière A, Loulergue C, Iacovoni J, Bernat S, Antoniou M, Vagner S.

Nucleic Acids Res. 2009 Aug;37(14):4672-83. doi: 10.1093/nar/gkp470. Epub 2009 Jun 8.

38.

The c.5242C>A BRCA1 missense variant induces exon skipping by increasing splicing repressors binding.

Millevoi S, Bernat S, Telly D, Fouque F, Gladieff L, Favre G, Vagner S, Toulas C.

Breast Cancer Res Treat. 2010 Apr;120(2):391-9. doi: 10.1007/s10549-009-0392-3. Epub 2009 Apr 30.

PMID:
19404736
39.

Post-transcriptional control of gene expression through subcellular relocalization of mRNA binding proteins.

Cammas A, Lewis SM, Vagner S, Holcik M.

Biochem Pharmacol. 2008 Dec 1;76(11):1395-403. doi: 10.1016/j.bcp.2008.05.022. Epub 2008 Jul 9.

PMID:
18582437
40.

Characterization of a short isoform of human Tgs1 hypermethylase associating with small nucleolar ribonucleoprotein core proteins and produced by limited proteolytic processing.

Girard C, Verheggen C, Neel H, Cammas A, Vagner S, Soret J, Bertrand E, Bordonné R.

J Biol Chem. 2008 Jan 25;283(4):2060-9. Epub 2007 Nov 26.

41.

Cytoplasmic relocalization of heterogeneous nuclear ribonucleoprotein A1 controls translation initiation of specific mRNAs.

Cammas A, Pileur F, Bonnal S, Lewis SM, Lévêque N, Holcik M, Vagner S.

Mol Biol Cell. 2007 Dec;18(12):5048-59. Epub 2007 Sep 26.

42.

Subcellular relocalization of a trans-acting factor regulates XIAP IRES-dependent translation.

Lewis SM, Veyrier A, Hosszu Ungureanu N, Bonnal S, Vagner S, Holcik M.

Mol Biol Cell. 2007 Apr;18(4):1302-11. Epub 2007 Feb 7.

43.

An interaction between U2AF 65 and CF I(m) links the splicing and 3' end processing machineries.

Millevoi S, Loulergue C, Dettwiler S, Karaa SZ, Keller W, Antoniou M, Vagner S.

EMBO J. 2006 Oct 18;25(20):4854-64. Epub 2006 Oct 5.

44.

Testosterone regulates FGF-2 expression during testis maturation by an IRES-dependent translational mechanism.

Gonzalez-Herrera IG, Prado-Lourenco L, Pileur F, Conte C, Morin A, Cabon F, Prats H, Vagner S, Bayard F, Audigier S, Prats AC.

FASEB J. 2006 Mar;20(3):476-8. Epub 2006 Jan 19. Erratum in: FASEB J. 2006 Jul;20(9):1573-4.

PMID:
16423876
45.

Chemical-based translational induction of luciferase expression: an efficient tool for in vivo screening of protein farnesylation inhibitors.

Boijoux O, Boutonnet C, Giamarchi C, Favre G, Vagner S, Faye JC.

Mol Pharmacol. 2005 Jun;67(6):1829-33. Epub 2005 Mar 22.

46.
47.

Pharmacological-based translational induction of transgene expression in mammalian cells.

Boutonnet C, Boijoux O, Bernat S, Kharrat A, Favre G, Faye JC, Vagner S.

EMBO Rep. 2004 Jul;5(7):721-7. Epub 2004 Jun 11.

48.

Generation of protein isoform diversity by alternative initiation of translation at non-AUG codons.

Touriol C, Bornes S, Bonnal S, Audigier S, Prats H, Prats AC, Vagner S.

Biol Cell. 2003 May-Jun;95(3-4):169-78. Review.

PMID:
12867081
49.

A single internal ribosome entry site containing a G quartet RNA structure drives fibroblast growth factor 2 gene expression at four alternative translation initiation codons.

Bonnal S, Schaeffer C, Créancier L, Clamens S, Moine H, Prats AC, Vagner S.

J Biol Chem. 2003 Oct 10;278(41):39330-6. Epub 2003 Jul 11.

50.

IRESdb: the Internal Ribosome Entry Site database.

Bonnal S, Boutonnet C, Prado-Lourenço L, Vagner S.

Nucleic Acids Res. 2003 Jan 1;31(1):427-8.

Supplemental Content

Loading ...
Support Center